Targeted therapy in advanced non-small-cell lung cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Advanced non-small-cell lung cancer (NSCLC) treatment has been enhanced by molecularly targeted therapies.
• Key pathways targeted include epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF).

Purpose of the Study:

• To review the current landscape of molecularly targeted therapies for advanced NSCLC.
• To highlight the roles of EGFR and VEGF pathways and their inhibitors.
• To discuss emerging treatment strategies and predictive markers.

Main Methods:

• Review of clinical trial data and FDA-approved targeted agents for NSCLC.
• Examination of preclinical and clinical studies on EGFR inhibitors (e.g., erlotinib).
• Analysis of studies on VEGF inhibitors (e.g., bevacizumab) and combination therapies.

Main Results:

• Erlotinib improves survival in previously treated advanced NSCLC patients.
• Bevacizumab demonstrated survival advantage when added to chemotherapy in advanced non-squamous NSCLC.
• Combination therapy with erlotinib and bevacizumab shows encouraging results with less toxicity.

Conclusions:

• Molecularly targeted therapies, particularly EGFR and VEGF inhibitors, are significantly impacting advanced NSCLC treatment.
• Predictive markers are crucial for selecting patients for targeted therapies.
• Combination strategies and novel agents are under active investigation to further improve outcomes.